CD8A and neoplasm: The outcomes demonstrated that the Apilimod + LNP@PTEN group attained the highest CD8+/CD4+ ratio (Figures 5F, H, Supplementary Figure S9), implying a more robust anti-tumor immune response relative to the other treatment groups.